SZLS.TO WACC - Weighted Average Cost of Capital

The WACC of StageZero Life Sciences Ltd (SZLS.TO) is 7.8%.

The Cost of Equity of StageZero Life Sciences Ltd (SZLS.TO) is 10.15%.

The Cost of Debt of StageZero Life Sciences Ltd (SZLS.TO) is 4.25%.

	Range	Selected
Cost of equity	7.80% - 12.50%	10.15%
Tax rate	25.90% - 26.50%	26.20%
Cost of debt	4.00% - 4.50%	4.25%
WACC	6.2% - 9.4%	7.8%

WACC

SZLS.TO WACC calculation

Category	Low	High

Long-term bond rate	3.2%	3.7%
Equity market risk premium	5.1%	6.1%
Adjusted beta	0.91	1.37

Additional risk adjustments	0.0%	0.5%
Cost of equity	7.80%	12.50%

Tax rate	25.90%	26.50%
Debt/Equity ratio	0.51	0.51
Cost of debt	4.00%	4.50%

After-tax WACC	6.2%	9.4%


Selected WACC	7.8%

SZLS.TO's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for SZLS.TO:

cost_of_equity (10.15%) = risk_free_rate (3.45%) + equity_risk_premium (5.60%) * adjusted_beta (0.91) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.